Valuation: Positron Corporation

Market Cap 56.49M 48.77M 45.76M 41.67M 78.36M 5.4B 79.45M 536M 210M 2.71B 212M 208M 9B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 55.36M 47.79M 44.84M 40.84M 76.79M 5.29B 77.85M 526M 206M 2.65B 208M 203M 8.82B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day+2.15%
1 week+18.38%
Current month+7.83%
1 month+15.15%
3 months-2.31%
6 months+1.06%
Current year+13.77%
1 week 1.64
Extreme 1.64
1.91
1 month 1.45
Extreme 1.45
1.91
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+18.38%+4.40%+38.20% 56.49M
-0.55%-4.35%-15.75%-18.75% 13.11B
+2.62%+10.27%+46.61%+17.55% 4.64B
-0.68%+0.49%-40.30%-51.96% 1.3B
-0.26%+21.69%-32.27% - 1.2B
+0.09%-1.04%-35.21%-37.86% 1.19B
+1.23%-2.49%+25.06%+81.00% 1.13B
-0.24%-3.47%+42.76%+144.12% 595M
-0.23%-3.52%+67.40% - 323M
+2.04%-1.12%-62.39%+300.21% 253M
Average +0.62%+1.33%+0.03%+59.06% 2.38B
Weighted average by Cap. +0.24%+0.58%-2.65%-0.98%

Financials

2024 2025
Net sales 588K 507K 476K 433K 815K 56.17M 826K 5.58M 2.19M 28.14M 2.21M 2.16M 93.61M 461K 398K 374K 340K 640K 44.12M 649K 4.38M 1.72M 22.1M 1.73M 1.69M 73.53M
Net income -2.38M -2.05M -1.93M -1.76M -3.3M -227M -3.35M -22.59M -8.85M -114M -8.93M -8.74M -379M -10.6M -9.15M -8.59M -7.82M -14.71M -1.01B -14.91M -101M -39.45M -508M -39.81M -38.95M -1.69B
Net Debt 1.42M 1.23M 1.15M 1.05M 1.98M 136M 2M 13.52M 5.3M 68.23M 5.35M 5.23M 227M -1.14M -981K -920K -838K -1.58M -109M -1.6M -10.79M -4.23M -54.42M -4.27M -4.17M -181M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
17/08/26 $1.720 -4.99% 3,446
14/08/26 $1.810 +4.04% 6,600
13/08/26 $1.740 -3.87% 39,687
12/08/26 $1.810 +13.12% 40,674
11/08/26 $1.600 -0.31% 38,922
  1. Stock Market
  2. Stocks
  3. POSC Stock